Crowdonomics
WatchlistPortfolio
REXIS BIOTECH, INC.

Reg CF · Preferred Stock · Dec 2023

ClosedReached targetReg CFPreferred Equity
via WeFunderView campaign
Raised
$469.9K / $1.2M max
38% of ceiling · target hit day 2
Investors
214
$2.2K avg
Post-money valuation
$12.5M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$477K$239K$0
2061030
Dec 14, 2023 · openedApr 11, 2024 · last reading
Target ($50K) hit — Dec 16, 2023, day 2Deadline Apr 29, 2024 — 18 days out

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via WeFunder; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2021–FY2022 · hover for source
$3.1M
$141K
FY2021
$8.4M
$894K
FY2022
RevenueNet income
Metric
FY2021 unaudited
FY2022 unaudited
Income statement
Revenue
$3,119,575
$8,400,823
Cost of goods sold
$1,293,815
$3,429,923
Gross margin
59%
59%
Net income
$140,884
$893,891
Taxes paid
$33,201
$0
Balance sheet
Cash
$48,195
-$121,220
Accounts receivable
$112,646
$4,565,035
Total assets
$2,509,831
$8,262,782
Short-term debt
$0
$0
Long-term debt
$0
$469,797
Total liabilities
$0
$469,797
Other
Headcount
—
22

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Pre-money$12M
Post-money$12.5M
Price / share$1.25
Shares offered44,248

Offering details

Target$50,000
Max$1,235,000
Min investment$100
OpenedDec 14, 2023
DeadlineApr 29, 2024
ClosedApr 11, 2024
Days active119

Links & provenance

Campaign pageSEC filing
Source: Manual
0001670254-23-001115

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.